Physician profile
Rita Karana Kathawa
NPI 1427584812
$6,066.54
in general payments reported to CMS, 2019-2025
23 companies · $3,258 in 2025
The $3,258 reported for 2025 was more than what 77% of Obesity Medicine (Internal Medicine) providers received nationally (typical 2025 total: $202).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $65.73 · 2021: $733 · 2022: $222 · 2023: $477 · 2024: $1,146 · 2025: $3,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,000 · Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,000.00 |
| Food and Beverage | $1,880.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $3,278.67 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novo Nordisk INC | $1,080.05 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $490.74 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Madrigal Pharmaceuticals | $182.38 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals Lp | $177.10 | 2023-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $124.74 | 2021 | |
| Abbott Laboratories | $110.87 | 2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $109.96 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $92.96 | 2023-2025 | Imcivree, Imcivree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.36 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.08 | 2022-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $49.66 | 2024-2025 | Recorlev |
| Amarin Pharma, INC. | $40.36 | 2021 | |
| Celgene Corporation | $37.98 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.96 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $22.65 | 2024 | Sucraid |
| Chiesi USA, INC. | $22.47 | 2025 | Myalept |
| Antares Pharma, INC. | $20.46 | 2023 | Nocdurna, Xyosted, Tlando |
| Pfizer INC. | $20.19 | 2020 | |
| Merck Sharp & Dohme LLC | $18.81 | 2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $18.26 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.08 | 2019 | |
| Currax Pharmaceuticals LLC | $13.75 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Kathawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.